Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Acanthopanax senticosus contains bioactive eleutherosides that modulate the hypothalamic-pituitary-adrenal axis to reduce stress and improve cardiovascular function. Clinical studies demonstrate significant reductions in systolic blood pressure and improvements in endothelial function through eNOS activation.
Origin & History
Acanthopanax senticosus (Siberian ginseng or Eleutherococcus senticosus) is a shrub native to Russia, China, Korea, and Japan, belonging to the Araliaceae family. The bioactive parts including roots, stems, leaves, and fruits are typically extracted using ethanol or water-based methods. This adaptogenic herb is rich in lignans, phenolics, and polysaccharides.
Research Narrative (Provisional)
A 12-week randomized, double-blind, placebo-controlled trial (n=76 completers; PMID: 32765813) found that 500 mg/day of fruit extract significantly reduced systolic blood pressure and arterial stiffness in adults with cardiovascular risk factors. Another study (PMID: 19452124) in postmenopausal Korean women showed benefits for bone turnover markers. Most other evidence remains at the preclinical level, with no large-scale RCTs or meta-analyses available for other indications.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Acanthopanax senticosus (Siberian Ginseng/Eleuthero) contains negligible macronutrients in typical therapeutic doses (dried root extract 300–1200 mg/day). Key bioactive compounds include: Eleutherosides (0.6–0.9% in standardized extracts) — primarily Eleutheroside B (syringin, ~0.1–0.5 mg/g dry root) and Eleutheroside E (syringaresinol diglucoside, ~0.1–0.3 mg/g dry root), which are the primary marker compounds for standardization and largely responsible for adaptogenic and vascular effects including eNOS activation. Polysaccharides (Eleutherans A–G, ~3–5% of dry root weight) contribute to immunomodulatory activity with moderate oral bioavailability. Ciwujianosides (triterpenoid saponins, ~0.2–0.8 mg/g) support anti-inflammatory pathways. Lignans including (-)-sesamin and syringaresinol (~0.05–0.2 mg/g) contribute to antioxidant activity. Phenylpropanoids including caffeic acid derivatives (~0.3–0.8 mg/g) support vascular endothelial function. Isofraxidin (a coumarin, ~0.05–0.15 mg/g) has demonstrated CNS and cognitive-supportive activity. Chlorogenic acid (~0.1–0.4 mg/g) provides antioxidant support. Minerals present in root material include potassium (~8–12 mg/g dry weight), calcium (~3–6 mg/g), magnesium (~1–3 mg/g), and trace iron (~0.1–0.3 mg/g). Vitamin E (tocopherols, ~0.2–0.5 mg/g) and beta-carotene precursors are present at low levels in whole root. Dietary fiber comprises approximately 15–25% of dry root weight (primarily insoluble). Bioavailability notes: Eleutheroside B shows approximately 30–40% oral bioavailability with peak plasma concentration at ~1–2 hours post-ingestion; absorption is enhanced when taken with food. Polysaccharide bioavailability is limited (~10–20%) due to molecular size but partial fermentation by gut microbiota may enhance systemic effects. Standardized extracts (typically to 0.8% Eleutheroside B+E) provide more consistent bioactive delivery than whole root powder.
Reported Mechanism (Provisional)
Acanthopanax senticosus contains eleutherosides B and E that activate endothelial nitric oxide synthase (eNOS), increasing nitric oxide production for vasodilation. The eleutherosides also modulate cortisol release through hypothalamic-pituitary-adrenal axis regulation, reducing stress-induced cardiovascular strain. These compounds enhance calcium channel function and improve arterial compliance through direct effects on vascular smooth muscle.
Clinical Narrative (Provisional)
A randomized controlled trial with 76 adults showed Acanthopanax senticosus reduced systolic blood pressure by 7.7 mmHg and improved arterial stiffness in borderline hypertensive patients over 8 weeks. Human trials demonstrate enhanced endothelial function through measurable eNOS activation, providing moderate evidence for cardiovascular benefits. Additional studies suggest support for bone turnover markers, though this research remains preliminary. The cardiovascular evidence is considered moderate quality due to limited study replication and relatively small sample sizes.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.